What's Happening?
Centivax, a biotechnology company based in South San Francisco, has successfully closed a $37 million financing round to advance its universal flu vaccine, Centi-Flu 01, into Phase 2 clinical trials. The financing was led by Structure Fund with contributions
from Meiji Seika Pharma Co., Ltd., Sigmas Group, Kendall Capital Partners, and Patrick and John Collison. This funding follows a previous $45 million Series A round completed in June 2025. Centivax's universal flu vaccine aims to provide broad and durable immunity against both seasonal and pandemic influenza strains by targeting conserved regions of the virus. The ongoing Phase 1 study involves over 300 participants and is designed to assess safety and efficacy against a wide range of influenza virus strains. The new funding will also support the advancement of other programs in Centivax's portfolio, including a cancer therapy, a malaria vaccine, and a universal antivenom.
Why It's Important?
The development of a universal flu vaccine by Centivax could significantly impact public health by providing more reliable protection against influenza, which currently requires annual reformulation and has variable effectiveness. The successful advancement of Centi-Flu 01 could reduce the global burden of influenza, which affects millions annually and poses a risk of pandemics. Additionally, the funding allows Centivax to continue developing its platform for other diseases, potentially addressing unmet medical needs in areas such as cancer and Alzheimer's disease. This progress underscores the potential of biotechnology innovations to transform healthcare and improve disease prevention strategies.
What's Next?
With the new financing, Centivax plans to initiate Phase 2 trials for Centi-Flu 01 in early 2027. The trial will involve 500 subjects and aims to demonstrate the vaccine's universal breadth and superiority over existing seasonal vaccines. The company also intends to advance its other clinical candidates to manufacturing and clinical readiness, positioning itself to address multiple high-impact medical conditions. Centivax's scalable manufacturing process will be deployed to support these efforts, potentially accelerating the path to commercialization and global access for its vaccines and therapies.
